IOCAS-IR  > 实验海洋生物学重点实验室
The Fluoro-Thiazolylhydrazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction
Zhang, Jiajia1,2,3; Dai, Jiajia4; Zheng, Qingxuan4; Guo, Shuju1,2,3; Yu, Yanyan4; Hu, Wenpeng4; Gao, Yanan4; Shi, Dayong1,2,3,4
2020-02-01
发表期刊INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷号21期号:3页码:15
通讯作者Shi, Dayong(shidayong@sdu.edu.cn)
摘要Triple negative breast cancer (TNBC) is the most aggressive cancer in women, and despite improved treatments, it remains a major cause of morbidity and mortality. We and others have demonstrated that different hybrid compounds targeting PARP/MAPK or other pathways to inhibit cancer progression may lead to promising therapeutic results. We introduced fluorine to alter the physical properties of the compounds. TSC-3C was one of the generated compounds. Upon treatment with TSC-3C, MDA-MB-231 cell proliferation, invasion, and migration were inhibited. TSC-3C induced MDA-MB-231 cell mitochondrial dysfunction and apoptosis, which may be caused by reducing the level of phosphorylated p44/42 MAPK (ERK1/2) and increasing the level of p-JNK. The present study may help to elucidate the role of the MAPK pathway in the development of breast cancer and may promote further research on halogenated heterocyclic compounds for the treatment of breast cancer.
关键词triple negative breast cancer MDA-MB-231 cells fluoro-thiazolylhydrazone MAPK pathway phosphorylated p44/42 MAPK (ERK1/2) phosphorylated c-Jun N-terminal kinase (p-JNK) apoptosis
DOI10.3390/ijms21031038
收录类别SCI
语种英语
资助项目NSFC-Shandong Joint Fund[U1706213] ; Sub-Class of Project of the National Natural Science Foundation of China[81803375] ; Surface Project of the National Natural Science Foundation of China[81773586] ; Surface Project of the National Natural Science Foundation of China[81872906] ; Sub-Class Project of the National Natural Science Foundation of China[81903354]
WOS研究方向Biochemistry & Molecular Biology ; Chemistry
WOS类目Biochemistry & Molecular Biology ; Chemistry, Multidisciplinary
WOS记录号WOS:000522551606024
出版者MDPI
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.qdio.ac.cn/handle/337002/167269
专题实验海洋生物学重点实验室
通讯作者Shi, Dayong
作者单位1.Chinese Acad Sci, Inst Oceanol, Key Lab Expt Marine Biol, Qingdao 266071, Peoples R China
2.Qingdao Natl Lab Marine Sci & Technol, Lab Marine Drugs & Bioprod, Qingdao 266071, Peoples R China
3.Univ Chinese Acad Sci, Coll Earth & Planetary Sci, Beijing 10049, Peoples R China
4.Shandong Univ, Inst Microbial Technol, State Key Lab Microbial Technol, Jinan 250014, Peoples R China
第一作者单位实验海洋生物学重点实验室
通讯作者单位实验海洋生物学重点实验室
推荐引用方式
GB/T 7714
Zhang, Jiajia,Dai, Jiajia,Zheng, Qingxuan,et al. The Fluoro-Thiazolylhydrazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2020,21(3):15.
APA Zhang, Jiajia.,Dai, Jiajia.,Zheng, Qingxuan.,Guo, Shuju.,Yu, Yanyan.,...&Shi, Dayong.(2020).The Fluoro-Thiazolylhydrazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction.INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,21(3),15.
MLA Zhang, Jiajia,et al."The Fluoro-Thiazolylhydrazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction".INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 21.3(2020):15.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
ijms-21-01038-v2.pdf(2858KB)期刊论文出版稿限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Jiajia]的文章
[Dai, Jiajia]的文章
[Zheng, Qingxuan]的文章
百度学术
百度学术中相似的文章
[Zhang, Jiajia]的文章
[Dai, Jiajia]的文章
[Zheng, Qingxuan]的文章
必应学术
必应学术中相似的文章
[Zhang, Jiajia]的文章
[Dai, Jiajia]的文章
[Zheng, Qingxuan]的文章
相关权益政策
暂无数据
收藏/分享
文件名: ijms-21-01038-v2.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。